TNFRSF17 and plasma cell myeloma: Bispecifics targeting antigens beyond BCMA, such as GPRC5D (GPRC5DxCD3, talquetamab, and RG6234) and FcRH5 (FcRH5xCD3, cevostamab), are in clinical development showing promising results for heavily treated myeloma.